In particular, GPBAR1/Gs interactions are involved in the prevention of diabetes and the reduction of inflammatory responses, making GPBAR1 a potential therapeutic target for several diseases, such as obesity or atherosclerosis. Here, GPBAR1 is linked to obesity due to melanocortin 4 receptor deficiency.